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Foxp3-expressing regulatory T (Treg) cells are essen-
tial for immune tolerance; however, the molecular
mechanisms underlying Treg cell expansion and
function are still not well understood. SUMOylation
is aprotein post-translationalmodification character-
ized by covalent attachment of SUMO moieties to
lysines. UBC9 is the only E2 conjugating enzyme
involved in this process, and loss ofUBC9completely
abolishes the SUMOylation pathway. Here, we report
that selective deletion of Ubc9 within the Treg line-
age results in fatal early-onset autoimmunity similar
to Foxp3 mutant mice. Ubc9-deficient Treg cells
exhibit severe defects in TCR-driven homeostatic
proliferation, accompanied by impaired activation
and compromised suppressor function. Importantly,
TCR ligation enhanced SUMOylation of IRF4, a crit-
ical regulator of Treg cell function downstream of
TCR signals, which regulates its stability in Treg cells.
Our data thus have demonstrated an essential role of
SUMOylation in the expansion and function of Treg
cells.
INTRODUCTION
Regulatory T (Treg) cells are essential in maintaining immune
tolerance and preventing autoimmune disorders (Josefowicz
et al., 2012; Sakaguchi et al., 2008). Foxp3 is the lineage-specific
transcription factor that determines Treg cell differentiation,
maintenance, and suppressor function (Fontenot et al., 2003;
Hori et al., 2003; Khattri et al., 2003; Williams and Rudensky,
2007). Mutation or deficiency of Foxp3 leads to fatal autoimmu-
nity both in mice and humans due to the absence of Treg cells
(Bennett et al., 2001; Brunkow et al., 2001). Constitutive expres-
sion of Foxp3 is required for establishing a distinct transcriptional
program in Treg cells by reinforcing the expression of Treg
signature genes (such as CTLA4, IL10, CD25, and GITR) while
repressing expression of genes associated with effector T cells
(Fontenot et al., 2005b; Gavin et al., 2007; Marson et al., 2007;Cell
This is an open access article under the CC BY-NWilliams and Rudensky, 2007; Zheng et al., 2007). Other tran-
scription factors, such as necrosis factor kB (NF-kB), NFAT,
RUNX1, EOS, and IRF4, cooperate with Foxp3 to establish or
stabilize the Treg transcriptional program (Long et al., 2009;
Ono et al., 2007; Pan et al., 2009; Wu et al., 2006; Zheng et al.,
2009). How post-translational modifications regulate these fac-
tors in response to environmental stimuli is unclear.
Foxp3+ Treg cells are initially derived from the thymus as
a result of a high-avidity interaction between T cell receptor
(TCR) and major histocompatibility complex class II (MHC
class II) molecules in the presence of CD28 costimulatory sig-
nals; common gamma-chain (gc) cytokines, especially inter-
leukin-2 (IL-2), provide an important second signal for Treg cell
differentiation (Josefowicz and Rudensky, 2009). After export
to the periphery, Treg cells must proliferate and differentiate
into effector Tregs to prevent autoimmunity or excessive im-
mune activation. Unlike conventional T cells, Treg cells have a
high proliferation rate counterbalanced with frequent apoptosis
in vivo (Pierson et al., 2013; Wang et al., 2012a), which is regu-
lated by the costimulatory molecule CD28 and cytokines like
IL-2 and IL-7 (Appleman et al., 2000; Fontenot et al., 2005a; Si-
monetta et al., 2012). A recent study revealed that TCR signaling
also plays an important role in peripheral Treg cell homeostasis
and function, especially for effector Tregs; inducible ablation of
TCR in mature Treg cells results in impaired activation, compro-
mised homeostatic proliferation and decreased suppressor
function, independent of FOXP3 expression, Treg signature
gene expression or the ability to sense IL-2 (Levine et al., 2014;
Vahl et al., 2014). However, themolecular pathways downstream
of TCR in peripheral Treg regulation are poorly understood.
SUMOylation is a reversible post-transcriptional modifica-
tion, involving covalent attachment of a SUMO moiety to a
lysine residue in the target protein. SUMOylation is involved in
many biological processes including nuclear organization, DNA
replication and repair, sub-nuclear localization, transcription,
meiosis, and signal transduction (Flotho and Melchior, 2013).
E1, E2, and E3 enzymes are involved in SUMOylation, which
can be reversed by SUMO-specific proteases (SENPs) (Flotho
and Melchior, 2013). As the only SUMO E2 in mammalian
cells, Ubc9 is indispensable for embryonic development at
the early post-implantation stage (Nacerddine et al., 2005).
In ROSA26-creERT2xUbc9fl/– mouse model, Ubc9 deletionReports 16, 1055–1066, July 26, 2016 ª 2016 The Author(s). 1055
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induced by 4-hydroxytamoxifen treatment mainly affects the
small intestine leaving other epithelial tissues unaffected (De-
marque et al., 2011). In myeloid cells, impaired SUMOylation
can promote Toll-like receptor (TLR)-induced production of
inflammatory cytokines and massive expression of type I inter-
feron signature genes without affecting the differentiation or
survival of bone marrow-derived dendritic cells (Decque et al.,
2016). These data indicate the pleiotropic and cell-fate-specific
roles of SUMOylation at different developmental stages.
The functional roles of SUMOylation in T cells have not been
well studied. SUMO-specific protease 1 (SENP1) is essential
for the early development of T and B cells; SENP1 deficiency
causes the accumulation of SUMOylated STAT5, thus blocking
STAT5 acetylation and subsequent signaling (Van Nguyen
et al., 2012). PIAS1, a SUMO E3 ligase, was shown to inhibit
Treg cell differentiation by maintaining a repressive chro-
matin state at Foxp3 promoter, indicating crosstalk between
SUMOylation and chromatin modification (Liu et al., 2010).
Whether SUMOylation is involved in Treg cell regulation and
the physiological consequence of SUMOylation deficiency in
Treg cells are unknown.
Here, we generated Treg cell-specificUbc9KOmice (Foxp3cre
Ubc9fl/fl) and find they develop fatal early-onset autoimmune dis-
ease. Ubc9-deficient Treg cells show defects in homeostatic
proliferation, impaired activation, and reduced suppressor capa-
bility. TCR-dependent gene expression in Treg cells is regulated
by UBC9-mediated SUMOylation with IRF4 stability, an impor-
tant transcription factor downstream of TCR, reduced in the
absence of UBC9. Thus, SUMOylation coordinates several key
aspects of Treg cell expansion and function.
RESULTS
Loss of Ubc9 in Treg Cells Leads to Fatal Early-Onset
Inflammatory Disorders
To investigate the role of UBC9-mediated SUMOylation in regu-
latory T cells, we generated mice with Treg cell-specific Ubc9
ablation by crossing mice harboring a conditional Ubc9 allele
(Ubc9fl) with Foxp3Cre mice expressing an YFP-Cre fusion pro-
tein under the control of endogenous Foxp3 locus (Rubtsov
et al., 2008). Ubc9 mRNA expression level was reduced by half
in CD4+YFP+ Treg cells of Foxp3creUbc9fl/wt male mice and
further reduced in those from Foxp3creUbc9fl/flmice (Figure S1A).
We then confirmed Ubc9 deficiency in CD4+ YFP+ Treg cells at
protein level from female Foxp3cre/wtUbc9fl/fl mice (Figure S1B).
All Foxp3creUbc9fl/fl mice developed severe autoimmune dis-
eases at 3 weeks of age, characterized by blepharitis and
dermatitis, reduced body size, extensive lymphadenopathy,
and splenomegaly (Figures 1A andS1C). CD4+ T cells in Foxp3cre
Ubc9fl/fl mice exhibited activated phenotype (CD44hiCD62Llo) in
peripheral lymphoid organs (Figure 1C), with increased expres-
sion of activation markers such as CD25, ICOS, CD69, GITR,
PD-1, and proliferation indicator Ki67 (Figure S1D). In addition,
diseasedmice showedmassive lymphocyte infiltration in kidney,
liver, lung, and salivary gland and succumbed to death at
3–5 weeks (Figures 1D and 1B).
All of these severe symptoms are reminiscent of the pheno-
types in Foxp3-deficient mice (Fontenot et al., 2003). Loss of1056 Cell Reports 16, 1055–1066, July 26, 2016Ubc9 in Treg cells resulted in increased percentage and number
of CD4+ T cells expressing interferon (IFN)-g, IL-4, IL-5, IL-13,
and IL-17A as well as CD8+ T cells expressing IFN-g, although
tumor necrosis factor a (TNF-a) or IL-2 production in CD4+
T cells were not elevated (Figures 1E and S1E; data not shown).
In addition, Foxp3creUbc9fl/fl mice showed notably increased
level of IgG1, IgG2a, IgG2b, and IgG3 as well as anti-dsDNA
auto-antibodies in serum compared with Foxp3creUbc9fl/wt litter-
mates (Figure S1F), which was associated with increased per-
centages of Tfh and GC B cells (Figures S1G and S1H). These
data suggest that Ubc9 expression in Treg cells is required to
systematically control Th1, Th2, Th17, effector CD8+ T, and
B cell responses.
Reduced Cell Number and Impaired Activation of Ubc9-
Deficient Treg Cells
In full agreement with the aforementioned severe autoimmune
diseases, Foxp3cre Ubc9fl/fl mice had decreased percentages
and numbers of CD4+ Foxp3+ Treg cells in lymph nodes and
spleen (Figures 2A and 2B). Ubc9-deficient Treg cells showed
decreased expression of many activation markers such as
CTLA4, ICOS, CD44, PD-1, Ki67, but not CD69, while CD62L
and CD25 expression maintained at high levels in lymph nodes
(Figure 2C). In contrast, loss of Ubc9 had little effect on Foxp3,
GITR, CD103, and CD127 expression (Figure 2C).
To assess the possibility that some of these phenotypes were
caused by the inflammatory signals in diseased mice, we exam-
ined Treg cells in 7-day-old Foxp3cre Ubc9fl/fl male mice, which
exhibited minimal inflammation (data not shown). Consistent
with the observation in Figure 2B, Ubc9-deficient Treg cells
showed reduced numbers (Figure S2A) and proliferation (Fig-
ure S2B) in the spleen, accompanied with impaired expression
of ICOS and PD-1 but largely normal expression of CD44 and
CD62L (Figure S2C; data not shown). Thus, in the disease-free
environment, Ubc9-deficient Treg cells have reduced numbers
and defective expression of ICOS and PD-1.
To examineUbc9-deficient Treg cells in a competitive environ-
ment, we analyzed CD4+ YFP+ Treg cells in female Foxp3cre/wt
Ubc9fl/fl and Foxp3cre/wtUbc9fl/wt littermates. Due to X chromo-
some random inactivation, Ubc9-sufficient CD4+YFP– Treg cells
safeguard the mice from autoimmunity in female Foxp3cre/wt
Ubc9fl/fl mice. Comparable CD4+ YFP+ Treg cells were found in
the thymus of Foxp3cre/wtUbc9fl/fl and Foxp3cre/wtUbc9fl/wt mice
(Figure S2D), suggesting that Ubc9 is not required for initial
Treg lineage development. However, Ubc9-deficient Treg cells
had a competitive disadvantage in the periphery of Foxp3cre/wt
Ubc9fl/fl mice (Figures S2D and S2E), with slightly reduced
expression of certain activation markers such as CTLA4 and
ICOS in disease-free setting (Figure S2F), similar to that of the
inflammatory environment. Inflammation signals were shown to
promote local Treg cell proliferation and activation. To address
the role of Ubc9 in inflammatory Tregs, female mice were
subjected to keyhole limpet hemocyanin immunization in the
presence of CFA. We found immunization augmented the cell
number reduction and the activation defect of Ubc9-deficient
Treg cells in draining lymph nodes after immunization (Figures
S2G–S2I). Taken together, these results suggest that loss of
Ubc9 in Treg cells leads to reduced cell numbers and defective
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Figure 1. Loss ofUbc9 in TregCells Leads to
Fatal Early-Onset Inflammatory Disorders
(A) Left panel: images of 28-day-old male mice,
thymus, peripheral lymphnodes,mesenteric lymph
node, and spleen.Right panel: total cellularity of the
lymph nodes, spleen, and thymus. n = 4–5 per
group.
(B) Survival curve of male mice.
(C) Flow cytometry analysis of CD44, CD62L
expression in CD4+ Foxp3– T cells of lymph nodes.
n = 3 per group.
(D) Histopathology of kidney, liver, lung, and sali-
vary gland by H&E staining; infiltrated lymphocytes
were indicated by black arrow. n = 4 per group.
Bars, 50 mM.
(E) Flow cytometry analysis of cytokines produced
by CD4+ Foxp3– T cells of lymph nodes. Lym-
phocytes were stimulated with PMA and Ion-
omycin for 5 hr in the presence of Golgi-Plug or
Golgi-Stop before staining CD4, Foxp3, and indi-
cated cytokines. n = 4 per group.
In (A)–(E) WT, Foxp3creUbc9fl/wt; KO, Foxp3cre
Ubc9fl/fl; LN, lymph nodes; SP, spleen; TH,
thymus. In (A) and (C)–(E), 21- to 23-day-old male
mice were used. In (A)–(E), values shown are
mean ± SD. A representative of three independent
experiments is shown. See also Figure S1.expression of activation markers in a cell-intrinsic manner, and
inflammatory signals can further enhance this defect.
Ubc9 Is Indispensable for Treg Cell Homeostatic
Proliferation
Treg-specific deletion of Ubc9 resulted in reduced Treg cells in
periphery but not in the thymus, suggesting that Ubc9 may be
required for Treg homing to periphery or their expansion there.
To address the homing issue, we transferred CD4SP thymocytes
isolated from Foxp3cre/wt Ubc9fl/wt or Foxp3cre/wt Ubc9fl/flmice to
CD45.1 congenic mice and found Ubc9-deficient thymic Treg
cells could home to lymph nodes and spleen normally (Fig-
ure S3A). In lymphopenic environment, Treg cells undergo ho-
meostatic proliferation induced by the combination of cytokines
and TCR stimulation (Gavin et al., 2002). To determine the role of
Ubc9 in this process, CellTrace-Violet-labeled CD4SP thymo-
cytes isolated from female Foxp3cre/wt Ubc9fl/fl or Foxp3cre/wt
Ubc9fl/wt mice were transferred to Rag1/ recipient mice.
Ubc9-deficient CD4+YFP+ Treg cells failed to proliferate (Fig-
ure 3A) or upregulate activation markers such as CTLA4, ICOS,
and CD25 (Figure 3B) but behaved normally in apoptosis (Fig-
ure S3B). Notably, Foxp3 expression was attenuated in Ubc9-Cell Rdeficient Treg cells after homeostatic
proliferation (Figure 3C), suggesting that
SUMOylation is required for maintaining
Foxp3 expression during Treg cell expan-
sion process. The proliferation defect was
further confirmed in vitro with anti-CD3
plus anti-CD28 stimulation and could not
be rescued by additional IL-2 or IL-7 (Fig-
ure 3D). Cell-cycle analysis revealed thatUbc9-deficient Treg cells accumulated at G2M phase with tetra-
ploid (4n) cell percentage twice as much as Ubc9-sufficient cells
(Figure 3E). In addition, Ubc9-deficient Treg cells tended to lose
Foxp3 expression upon TCR stimulation accompanying cell divi-
sion (Figures S3C and S3D), which was reminiscent of the phe-
notypes in CNS2-deficient Treg cells (Feng et al., 2014; Li
et al., 2014). Bisulfite sequencing of CNS2 region of purified
CD4+YFP+ Treg cells from male mice showed that Ubc9-defi-
cient Treg cells did not fully maintain the hypomethylation state
as wild-type (WT) Treg cells do, especially after proliferation (Fig-
ure S3E), indicating the requirement of SUMOylation for Treg-
specific epigenetic maintenance and thereby Foxp3 stability.
Next, we investigated the signaling pathways potentially
contributed to the proliferation defect. Of cytokine signaling
pathways, IL-2 and IL-7 are most critical for Treg cell homeo-
static proliferation (Gavin et al., 2002; Simonetta et al., 2012).
However, phosphorylated STAT5 was comparable inUbc9-defi-
cient and Ubc9-sufficient Treg cells both before and after IL-2 or
IL-7 stimulation (Figures S4A and S4B). This could be further
supported by the high level of CD25 (a chain of IL-2 receptor)
and normal level of CD127 (a chain of IL-7 receptor) expression
in Ubc9-deficient Treg cells (Figure 2C).eports 16, 1055–1066, July 26, 2016 1057
A B
C
Figure 2. Reduced Cell Number and Impaired Activation of Ubc9-Deficient Treg Cells
(A and B) Percentage and cell number of CD4+ Foxp3+ Treg cells of lymph nodes, spleen, and thymus. n = 4–5 per group. Values shown are mean ± SD.
(C) Flow cytometry analysis of indicated molecules on CD4+ Foxp3+ T cells of lymph nodes. n = 3 per group.
In (A)–(C), WT, Foxp3creUbc9fl/wt; KO, Foxp3creUbc9fl/fl; LN, lymph nodes; SP, spleen; TH, thymus; 21- to 25-day-old male mice were used; a representative of
three independent experiments is shown. See also Figure S2.Based on these data, we reasoned that TCR signaling
pathway might be responsible for the proliferation defect of
Ubc9-deficient Treg cells. We analyzed ERK, NF-kB, NFAT
signaling pathways downstream of TCR in Ubc9-deficient
TH0 cells using creERT2 system (Figure S4I). Moreover, phos-
phorylated ERK, P38, AKT, S6, and calcium influx were de-
tected directly in Ubc9-deficient Treg cells by phosphoflow
(Figures S4C–S4H). However, most of the pathways detected
were largely intact except AKT and S6. Ubc9-deficient Treg
cells showed reduced AKT S473 phosphorylation and slight
decrease in S6 phosphorylation (Figures S4D and S4E), espe-
cially in the inflammatory environment (Figure 3F). mTOR inte-
grates immune signals, environmental cues, and nutrients in
T cells and regulates protein translation, cell growth, and sur-
vival (Chi, 2012). Treg cells depend on mTORC1 for homeo-
stasis and function, with S6 as the direct target of mTORC1
(Zeng et al., 2013). mTORC2, a regulator downstream of
TCR signals (Vahl et al., 2014), can directly phosphorylate
AKT at serine 473 and thereby inhibiting constitutively active
FoxO1, which can promote effector Treg cell differentiation
and migration (Luo et al., 2016). Furthermore, AKT itself is
a SUMO target and SUMOylation can promote AKT kinase
activity to control cell survival and proliferation (Li et al.,
2013). Thus, SUMOylation is required for TCR-mediated1058 Cell Reports 16, 1055–1066, July 26, 2016Treg cell homeostatic proliferation through regulating mTOR-
AKT signaling pathway.
To gain an overview of SUMOylated proteins in T cells, we
purified endogenous SUMO2 conjugates in EL4 cell line and
analyzed by mass spectrum. Overall, 215 proteins were identi-
fied in this experiment, including those reported by published
literatures such as TRIM28, RanGAP-1, PML, BHLHE40, and
TOP2A (Dawlaty et al., 2008; Li et al., 2007; Mahajan et al.,
1997; Shen et al., 2006; Wang et al., 2012b). Unbiased gene
ontology (GO) analysis revealed that SUMOylated proteins
were most enriched in translation, RNA processing, ribonucleo-
protein complex protein biogenesis, ribosome biogenesis, PML
body organization, DNA topological change, and so on (Fig-
ure S4J), many of which are essential biological process and
involved in cell proliferation.
Diminished Expression of Multiple Suppressor
Molecules in Ubc9-Deficient Treg Cells
In addition to the proliferation defect, impaired expression of
activation markers led us to consider whether Ubc9-deficient
Treg cells are functionally competent. To address this question,
we performed in vitro suppression assay. Ubc9-deficient Treg
cells sorted from healthy Foxp3cre/wtUbc9fl/flmice were still func-
tional but slightly less efficient compared with their wild-type
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Figure 3. Ubc9 Is Required for Treg Cell Pro-
liferation
(A–C) CellTrace-Violet-labeled CD4SP thymocytes
were transferred intoRag1/mice, and dye dilution
was analyzed 7 days after transfer. n = 3 per group.
(A) CellTrace Violet dilution, percentage of non-
proliferating cells, and Ki67 MFI after homeostatic
proliferation. (B) MFI of CTLA4, ICOS, CD25 of
CD4+YFP+ Treg cells after homeostatic prolifera-
tion. (C) Flow cytometry analysis of Foxp3 expres-
sion and Foxp3 MFI. MFI, mean fluorescence in-
tensity.
(D) CellTrace-Violet-labeled CD4+ YFP+ Treg cells
were stimulated by anti-CD3/CD28 for 3 days with
or without IL-2 or IL-7; dye dilution was analyzed by
flow cytometry.
(E) Flow cytometry analysis of cell cycle of CD4+
YFP+ Treg cells after anti-CD3/CD28 stimulation by
DAPI staining.
(F) CD4+ YFP+ Treg cells were stimulated with PMA
and Ionomycin for 15 min; phosphorylated AKT-
S473 and S6 were stained. n = 3 per group; WT,
Foxp3creUbc9fl/wt; KO, Foxp3creUbc9fl/fl.
In (A)–(E), WT, Foxp3cre/wtUbc9fl/wt; KO, Foxp3cre/
wtUbc9fl/fl. In (A)–(F), values shown are mean ± SD.
ns, no significance. A representative of three inde-
pendent experiments is shown. See also Figures S3
and S4.counterparts (Figure 4A). Since reversal of anergy has been sug-
gested to impair Treg function, we also analyzed this possibility
and found Ubc9 KO Treg cells well retained the anergic state as
WT (data not shown). Putative suppressor effector molecule like
CTLA4 failed to be upregulated in Ubc9-deficient Treg cells in
this process or by anti-CD3/CD28 plus IL-2 stimulation (Figures
4B and 4C). In addition, transforming growth factor b (TGF-b)-
induced iTreg differentiation from female naive T cells was quite
normal at day 3 but impaired at day 4 in the absence of Ubc9
(Figure S5A). Moreover, we examined the suppressor function
of YFP+ iTreg and found a profound defect without Ubc9 (Fig-
ure S5B). Taken together, partial loss of function and remarkable
defect in proliferation may contribute to the fatal early-onset
autoimmune disease in Foxp3cre Ubc9fl/fl mice.
To gain insights into the mechanism underlying defective Treg
function upon Ubc9 deletion, we performed RNA sequencing
(RNA-seq) using CD4+YFP+ Treg cells sorted from lymph nodes
and spleen of Foxp3cre/wtUbc9fl/wt or Foxp3cre/wtUbc9fl/fl mice.
In total, loss of Ubc9 affected the expression of 365 genes by
at least 1.5-fold (p < 0.05) and 149 genes at least 2-fold (p <
0.01), and 92 genes were downregulated by 2-fold in Ubc9-defi-Cellcient Treg cells. To get an overview of tran-
scriptome, we performed GO analysis
of genes with at least 1.5-fold change us-
ing DAVID Bioinformatics Resources 6.7
(https://david.ncifcrf.gov/) (Huang et al.,
2009). On one hand, genes upregulated
in Ubc9-deficient Treg cells were enriched
in regulation of transcription, ribosome,
RNA metabolic process, translation, and
proliferation, which is consistent with otherreports that SUMOmodification mainly inhibits transcription and
actively participates in meiosis (Figure S6A). On the other hand,
genes downregulated by Ubc9 deletion were mainly enriched in
immune responses, including cytokine binding and production,
chemokine receptor activity, IL-1 receptor activity, and regula-
tion of lymphocyte activation (Figure S6A), indicating that
SUMOylation is required for the full immune function of Treg
cells.
To further explore the functional defect in Ubc9-deficient
Treg cells, we analyzed the putative suppressor molecules
based on RNA-seq data and further confirmed by RT-PCR
(Figures 4D–4F). In agreement with the protein expression de-
tected by flow cytometry, many suppressor molecules in Treg
cells were downregulated upon Ubc9 deletion, including
CTLA4, ICOS, CD44, PD-1, LAG3, Granzyme B, Perforin-1,
CD38, CD39, and NT5E. In terms of suppressive cytokines
(Rubtsov et al., 2008; Shevach, 2009), IL-10 but not TGF-b
expression was severely impaired in Ubc9-deficient Treg cells
(Figures 4D–4F). A recent study also suggested that chemo-
kine receptors are required for Treg cells to migrate to the in-
flammatory sites to execute their anti-inflammation functionReports 16, 1055–1066, July 26, 2016 1059
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Figure 4. Ubc9 Is Required for Treg Cell Func-
tional Activity
(A) Peripheral CD4+YFP+ Treg cells sorted form
female mice were co-cultured with CellTrace-Violet-
labeled wild-type naive T cells (Tresp) in the pres-
ence of anti-CD3 and mitomycin-treated splenocytes
(APCs) for 84 hr, dye dilution and cell division index
were analyzed by FlowJo, and the percentage of
proliferated cells was shown. A representative result
of two independent experiments is shown.
(B) mRNA expression of CTLA4 in CD4+YFP+ Treg
cells after anti-CD3/CD28 and IL-2 stimulation for
indicated time. Values shown are mean ± SD.
(C) Flow cytometry analysis of CTLA4 expression on
Treg cells in (A).
(D and E) RNA-seq was performed using peripheral
CD4+YFP+ Treg cells sorted from healthy female
mice. Each sample contained pooled Treg cells from
five to ten mice. (D) Expression patterns of potential
suppressor molecules and chemokine receptors in
Treg cells. Heatmaps depict the absolute value of
RPKM (reads per kilobases per million reads, Log2-
transformed). (E) Genes expressed in Ubc9-sufficient
Treg cells (WT) were plotted against those expressed
in Ubc9-deficient Treg cells (KO); genes shown in (C)
are indicated by red dots.
(F and G) qPCR confirmation of relative expression of
selected genes shown in (C) and (D). Values shown
are mean ± SD. ns, no significance. A representative
of two independent experiments is shown.
In (A)–(G), WT, Foxp3cre/wtUbc9fl/wt; KO, Foxp3cre/wt
Ubc9fl/fl. 5-week-old female mice were used. See also
Figure S5.(Ding et al., 2012). Indeed, Ubc9-deficient Treg cells had
compromised expression of many chemokine receptors such
as CXCR3, CCR6, CXCR5, and CCR2 (Figures 4D, 4E, and
4G). CCR6 regulates the migration of Treg cells to TH17 accu-
mulation sites (Yamazaki et al., 2008), while CXCR3 and
CXCR6 expressed by TH1 are also important for Treg cells
to control TH1 inflammation (Ding et al., 2012). CXCR5 is
highly expressed by Tfr cells, which are involved in restraining
B cell response through inhibition of Tfh cell function (Crotty,
2011). Thus, we proposed that diminished expression of sup-
pressor molecules and defective migration to inflammation
sites both contribute to the defective suppressive function of
Ubc9-deficient Treg cells.1060 Cell Reports 16, 1055–1066, July 26, 2016Regulation of TCR Signaling Pathway
by Ubc9 in Treg Cells
Unbiased analysis of gene expression pro-
file against public available database at the
GSEA server of the Broad Institute (http://
software.broadinstitute.org/gsea/index.jsp)
(Mootha et al., 2003; Subramanian et al.,
2005) revealed that loss of Ubc9 mainly
affected the gene sets of inflammatory
response, Foxp3-targeted genes, adhesion
molecules, Treg signature genes and activa-
tion/effector phenotype (Table S1). In terms
of Treg signature genes, more than 32%(104/322) of genes were affected at least 1.5-fold, the majority
of which (76/104) were downregulated by Ubc9 deletion. Among
genes whose expression level changed at least 2.5-fold (p <
0.05), 21 genes were downregulated, while only one gene was
upregulated (Figure 5A), indicating Treg cellular identity is
largely maintained. Although Foxp3 expression was normal
at steady state, 22% of genes regulated by Foxp3 were affected
by Ubc9 deletion for at least 1.5-fold (Figure 5B), suggesting
other factors cooperating with Foxp3 might be regulated
by Ubc9. Among these Ubc9 regulated genes, Foxp3-acti-
vated genes were mostly downregulated (80%), while Foxp3
repressed genes were mostly upregulated (71%) by Ubc9 dele-
tion (Figure 5B), suggesting that UBC9-mediated SUMOylation
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Figure 5. Ubc9-Dependent Genes in TregCells
Are Associated with TCR Signals and Corre-
lated with IRF4 Targets
(A–F) Normalized enrichment scores (NES) and false
discovery rate (FDR) were calculated at the GSEA
server of the Broad Institute. Gene sets associated
with Treg signature (A) and gene sets regulated by
Foxp3 (B), TCR (C), c-REL (D), NFAT (E), and IRF4 (F)
were analyzed by GSEA using the above RNA-seq
results.
For (A), differentially expressed genes with fold
change >1.5 are shown in pie (red, upregulated genes
in KO, blue, downregulated genes in KO), while genes
with fold change >2.5 (p < 0.05) are shown in the
heatmap. For (C)–(F), differentially expressed genes
with fold change >1.5 are shown in pie (red, upregu-
lated genes in KO; blue, downregulated genes in KO),
and genes with fold change >2 (p < 0.05) are shown in
the heatmap. The plots in (C) and (F) show the dis-
tribution of the genes (‘‘hits’’) against the ranked list of
genes. Gene list in (C) shows the representative
genes with diminished expression in Ubc9 KO Treg
cells within the gene set regulated by TCR. Heatmaps
depict KO to WT fold-change values (Log2-trans-
formed). WT, Foxp3cre/wtUbc9fl/wt; KO, Foxp3cre/wt
Ubc9fl/fl. See also Figure S6 and Table S1.facilitates Foxp3 to exert its master regulation function in Treg
cells.
Recent studies showed that TCR signals are indispensable for
effector Treg cells differentiation, homeostatic proliferation, and
function, although not for Foxp3 expression and IL-2 responsive-
ness (Levine et al., 2014; Vahl et al., 2014). Ubc9-deficient Treg
cells were quite similar to TCR-ablated Treg cells, suggesting
that UBC9-mediated SUMOylation are involved in TCR signaling
pathway. To test this, we further analyzed the gene expres-
sion profile using gene-set enrichment analysis. Our results
showed that TCR-dependent gene expression was significantly
disturbed due to Ubc9 deletion (false discovery rate [FDR] =
0.00) (Figure 5C), and most of which were downregulated in
Ubc9-deficient Treg cells. Furthermore, we checked a series
of transcription factors downstream of TCR signals. Genes tar-
geted by Egr2 or NF-kB were largely unaffected in the absence
of Ubc9 in Treg cells (Figures S6B and S6C). Nevertheless,
c-Rel-controlled genes were partially downregulated in Ubc9-
deficient Treg cells (Figure 5D). More than 30% NFAT-targetedCegenes were disturbed upon Ubc9 deletion,
although calcium influx was intact in Ubc9-
deficient Treg cells (Figures 5E and S4H).
Interestingly, IRF4-controlled genes had
the most significant defect due to Ubc9
depletion, with 67% of IRF4-dependent
genes downregulated at least 1.5-fold, and
only one gene was upregulated in Ubc9-
deficient Treg cells (Figure 5F), consistent
with its important role of effector Treg cell
differentiation.
Taken together, although Ubc9-deficient
Treg cells maintainmost of the Treg identity,TCR-dependent gene expression landscape largely relies on
UBC9-mediated SUMOylation, and these TCR-regulated genes
are mainly controlled by c-Rel, NFAT, and, most importantly,
IRF4.
SUMOylation Promotes IRF4 Protein Stability and
Function in Response to TCR
IRF4 in Treg cells was reported to control TH2 response coop-
erating with Foxp3; IRF4-deficient Treg cells lost expression of
a subset of suppressor molecules such as ICOS, IL10, EBI3,
GZMB, and FGL2 (Zheng et al., 2009). In our study, since
IRF4-targeted genes were mostly affected by Ubc9 deletion,
we were particularly curious about whether IRF4 could be
modified by SUMOylation. To address this question, we over-
expressed SUMO1 or SUMO2, UBC9 and IRF4 in 293T cells.
We found that IRF4 could be SUMOylated selectively by
SUMO2 in 293T cells (Figures 6A and S7A). To identify
SUMO-targeted lysine, we applied mutagenesis approach on
several lysine residues either predicted by software or impliedll Reports 16, 1055–1066, July 26, 2016 1061
Figure 6. IRF4 Is SUMOylated at K349 in
T Cells
(A) 293T cells were transfected with indicated
plasmids expressing His-tagged SUMO1 or
SUMO2, Flag-tagged IRF4 and HA-tagged UBC9.
Flag tag IP was performed in denatured condition;
elution was immunoblotted with anti-Flag or anti-
His antibodies.
(B) Flag-UBC9 was fused to the N terminus of
IRF4; Flag tag IP was performed as in (A).
(C and D) Primary CD4+ T cells were infected with
retrovirus expressing Flag-tagged UBC9-IRF4
(IRF4 WT or IRF4 K349R mutant) and stimulated
with PMA and Ionomycin for 1 hr. Flag tag IP was
performedas in (A); elutionwas immunoblottedwith
anti-Flag antibody (C) or anti-SUMO2 antibody (D).
For (A)–(D), SUMOylated bands are indicated
by arrow. A representative of at least three inde-
pendent experiments is shown. NT, no treatment.
P+I, treated with PMA and Ionomycin. See also
Figure S7.by other IRF4 family members and found K349 was the SUMO-
targeted lysine in our case (Figure S7B). Furthermore, we
confirmed K349 as the major SUMOylation site using UBC9
fusion-directed SUMOylation (UFDS) method (Figure 6B) (Ja-
kobs et al., 2007).
To test whether IRF4 could be SUMOylated in T cells, UBC9-
IRF4 fusion protein was overexpressed in primary CD4+ T cells
by retroviral infection, and cells were stimulated with PMA and
Ionomycin for 1 hr before collection. Consistent with the results
in 293T cells, we found that IRF4 could be SUMOylated in
primary T cells, and K349R mutation abolished most of the
SUMOylation band (Figures 6C and 6D). More interestingly,
IRF4 SUMOylation was enhanced by TCR stimulation (Figures
6C and 6D). Next, to investigate the function of SUMOylation
on IRF4 transcriptional activity, we performed a dual-luciferase
assay using murine IL-4 promoter in Jukart T cells, in which
IRF4 expression was comparable in both groups due to the
constitutive expression driven by exogenous promoter. We
found that K349R mutation affected IRF4-induced luciferase
expression both before and after TCR stimulation (Figure 7A),
indicating that SUMOylation is required for IRF4 in order to fully
exert its function in T cells.
Flow cytometry data showed that IRF4 expression was
reduced at protein level in Ubc9-deficient Treg cells (Figure 7B),
while IRF4 mRNA expression was not altered, even after anti-
CD3, anti-CD28, and IL-2 stimulation (Figure S7C), which
suggests that IRF4 stability might be regulated at protein level.
To assess this hypothesis, we overexpressed the IRF4-IRES-
GFP cassette in primary T cells and stimulated the cells with
PMA and Ionomycin in the presence of CHX (cycloheximide)
for different time. Compared with WT IRF4, SUMO-deficient
IRF4 (IRF4 K349R) showed significantly decreased stability,
and this defect can be rescued by MG132 treatment (Fig-
ure 7C), indicating that SUMOylation could protect IRF4 from1062 Cell Reports 16, 1055–1066, July 26, 2016proteasome-mediated protein degrada-
tion. Taken together, TCR signals can
promote IRF4 protein stability thoughIRF4 SUMOylation, thus endowing suppressive function in
Treg cells.
DISCUSSION
SUMOylation, as critical post-translational modification in eu-
karyotic cells (Mahajan et al., 1997; Matunis et al., 1996), is not
well studied in the immune system. Our current study demon-
strated the functional consequence of global SUMOylation
ablation in Treg cells. Ubc9 deficiency in Treg cells led to
catastrophic early-onset autoimmunity. We found that Ubc9 is
required for Treg cell homeostatic proliferation, activation, and
suppressor function, and loss of Ubc9 disturbed the gene
expression program driven by TCR signaling. Interestingly, we
identified TCR-regulated SUMOylation of IRF4, which enhances
its stability and activity.
Many post-translational modifications (PTMs) including acety-
lation, ubiquitination, and phosphorylation can modulate Foxp3
activity by altering DNA binding, transactivation, and protein
stability (van Loosdregt and Coffer, 2014). In our case, we
were unable to detect Foxp3 SUMOylation in Treg cells. Foxp3
expression is well maintained in Ubc9-deficient Treg cells at
steady state; only about 20% of Foxp3-targeted genes are
moderately influenced by Ubc9 deletion. However, when stimu-
lated with anti-CD3/CD28, Ubc9-deficient Treg cells lost Foxp3
preferentially, underscored by increased CNS2 methylation.
This is not likely attributed to reduced IRF4 expression, since
IRF4 knockdown did not affect Foxp3 expression (data not
shown). Thus, we proposed that maintenance of Treg cell-
specific methylation pattern and thereby Foxp3 stability upon
TCR stimulation are largely dependent on UBC9-mediated
SUMOylation.
IRF4, as a cooperator of Foxp3, is required for Treg cells to
control TH2 response (Zheng et al., 2009). IRF4 also plays an
AB
C
Figure 7. SUMOylation Promotes IRF4 Protein Stability and Function
(A) Left panel: plasmids containing IRF4 WT or IRF4 K349R mutant (GFP was located downstream of IRF4 via IRES) were transfected together with luciferase
reporter driven by murine IL-4 promoter into Jurkat cells via electroporation. Renilla vector was used as an inner control and the ratio of luciferase to Renilla was
shown. Right panel: western blot of IRF4 expression using anti-Flag antibody.
(B) Flow cytometry analysis of IRF4 protein expression in CD4+YFP+ Treg cells of Foxp3cre/wtUbc9fl/wt (WT) and Foxp3cre/wtUbc9fl/fl (KO) mice.
(C) Primary CD4+ T cells were infected with retrovirus expressing Flag-tagged IRF4 in the presence of CHX (Cycloheximide) for indicated time. MG132was added
to block proteasome degradation. Relative protein content was measured by ImageJ software.
For (A)–(C), a representative of at least three independent experiments is shown. nosti, no stimulation. sti, stimulation with PMA and Ionomycin for 4 hr. See also
Figure S7.important role in the differentiation and function of effector
Treg cells (Cretney et al., 2011). Our study revealed that many
activation markers and suppressor molecules affected by
Ubc9 deletion are regulated by IRF4. Moreover, IRF4 stability
and activity are regulated by TCR and SUMOylation, and IRF4
expression is reduced at protein level in Ubc9-deficient Treg
cells. Foxp3creIrf4fl/flmice are succumbed to autoimmune symp-
toms including lymphadenopathy, weight loss, blepharitis, anddermatitis, with notable increase of Th2 cytokines and marginal
increase of IL-17A, similar to Foxp3creUbc9fl/fl mice, although
the disease in the latter case is much earlier in onset (3–4 weeks
versus 6–8 weeks). Foxp3creUbc9fl/fl mice showed more robust
production of IFN-g, which could be explained by the numerical
decrease ofUbc9-deficient Treg cells and a systematic failure to
control immune homeostasis (Dadke et al., 2007). However, IRF4
overexpression failed to rescue the proliferation defect in Ubc9Cell Reports 16, 1055–1066, July 26, 2016 1063
KO Treg cells (data not shown). Since SUMOylation is intensively
involved in meiosis, other important players might contribute to
this defect. Thus, we consider that IRF4 might be the tip of
iceberg in the world of SUMOylation, though it may be associ-
ated with the defective differentiation and function inUbc9-defe-
cient Treg cells. In addition, it further supports the concept that
Foxp3 is not the sole regulator in Treg cells; signaling-dependent
post-translational modifications of its cooperators are needed
for Treg cell maturation and function.
Although IL-2 and IL-7 are most important cytokines for Treg
cell homeostatic proliferation, their downstream signaling lead-
ing to STAT5 phosphorylation was unaffected in Ubc9-deficient
Treg cells. Moreover, the addition of IL-2 or IL-7 in vitro did not
rescue the proliferation defect. This phenomenon correlates well
with that seen in TCR-deleted Treg cells (Levine et al., 2014;
Vahl et al., 2014), which can further support our hypothesis
that Ubc9 deletion mainly affects the TCR signals. In Treg cells,
mTOR inhibition has been shown to induce Foxp3 expression
(Haxhinasto et al., 2008); Mtor-deficient T cells fail to differen-
tiate into effector T cells but tend to promote Foxp3 expression
in response to TCR stimulation (Delgoffe et al., 2009). However,
Treg cells also depend on mTORC1 for homeostasis and func-
tion induced by TCR and IL-2 (Zeng et al., 2013). mTORC2, a
regulator downstream of TCR signals (Vahl et al., 2014), can
directly phosphorylate AKT at serine 473 and thereby inhibit
constitutively active FoxO1, which can promote effector Treg
cell differentiation and migration (Luo et al., 2016). Furthermore,
mTOR-AKT inhibition can block Treg cell proliferation (data not
shown). In our study, decreased phosphorylation of mTORC1
target S6 and reduced AKT-S473 phosphorylation revealed
the attenuated mTOR signals as a result of Ubc9 deletion.
SUMOylation usually functions in a fine-tuned, reversible way;
although the reduction is moderate, this decrease in mTOR
function might still be important for Treg cell homeostatic prolif-
eration, migration, and function when challenged with strong
immune signals.
Previous study suggests that SUMOylation preferentially
affects the proliferating cells rather than non-proliferating or
terminally differentiated cells (Demarque et al., 2011). Periph-
eral Treg cells can be functionally divided into two distinct
subsets, including central Tregs as the majority of Treg cell
population and effector Tregs activated by antigens and prolif-
erate rapidly (Liston and Gray, 2014). Our study revealed that
loss of Ubc9 in Treg cells resulted in impaired proliferation
and defective activation, suggesting the failure of effector
Treg cell differentiation and maturation. However, it does not
necessarily indicate that central Treg cells are not affected by
Ubc9 deletion, since the effector Treg cell defect alone could
not explain the significant reduction in total Treg cell number
in Foxp3creUbc9fl/fl mice. Actually, central Treg cells exhibit
even higher extent of SUMOylation compared with effector
Treg cells (data not shown), it is possible that SUMOylation
can promote central Treg cell survival and help to keep them
in a quiescent state.
In summary, our study has uncovered a critical function of
SUMOylation in regulation of Treg cell homeostatic proliferation
and function in vivo. This study opens up an avenue for future
identification of SUMO targets in immune tolerance and function.1064 Cell Reports 16, 1055–1066, July 26, 2016EXPERIMENTAL PROCEDURES
Additional detailed methods can be found in the Supplemental Experimental
Procedures.
Mice
Ubc9 fl/flmice were backcrossed to C57BL/6 mice strain for at least six gener-
ations. Foxp3cre mice were all kept on a C57BL/6 genetic background. Exper-
imental mice were age matched and housed under specific-pathogen free
conditions in Animal Facility of Tsinghua University. All animal protocols are
approved by governmental and institutional guidelines for animal welfare.
Plasmid Construction
For pRVKM-Flag-UBC9-IRF4 plasmid, mouse Ubc9 gene was amplified from
cDNA of mouse primary T cells, and SalI-Ubc9-XhoI cassette without stop
codon was cloned to RV-GFP retrovirus vector (gift of K. Murphy) by XhoI
site downstream of 3xFlag tag; mouse IRF4 was clone from cDNA of mouse
TH17 cells, and XhoI-IRF4-SnaBI cassette with stop codon was cloned to the
downstream of Ubc9 to generate the Ubc9-Irf4 fusion gene. K349R mutation
was generated byGibson AssemblyCloning Kit. GFPwas located downstream
of IRF4 via IRES, which is transcribed with IRF4 but translated independently.
In Vitro Suppressive Assay
2 3 104 Celltrace-Violet-labeled naive CD4+ T cells were co-cultured with
different numbers of CD4+ YFP+ Treg cells in the presence of 5 3 105 mito-
mycin treated spleenocytes and 2 mg/ml anti-CD3 in round-bottom 96-well
plate for 3 days or 4 days. Cell proliferation was detected by Celltrace Violet
dilution by flow cytometry.
Statistical Analysis
Data were analyzed by Graph Prism 6.0 software, statistical analysis of the
results was performed by unpaired Student’s t test as indicated. p values
are presented in figure legends where a statistically significant difference
was found: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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